The U.S. Food and Drug Administration announced recently that it will not review Moderna’s mRNA flu vaccine, despite late-stage trials showing it was safe and effective. The rejection has many in and ...
ArgenTag have joined PacBio’s Compatible Partner Program and opened a grant to provide access to single-cell sequencing tech.
In a major blow to vaccine development, the FDA said it will not review Moderna’s application for the first mRNA-based flu shot.
The FDA’s refusal to review Moderna’s mRNA-based flu vaccine is “part of a disturbing pattern” of moving regulatory goalposts, according to Clay Alspach, executive director of the Alliance for mRNA ...
Leveraging its integrated "design-synthesis-quality control" system, Creative Biolabs is overcoming bottlenecks in mRNA ...
The Food and Drug Administration rejected Moderna's new flu shot. This raises questions about what it means for the future of ...
Researchers tracked more than 400 toddlers to see whether mRNA COVID-19 vaccination during or just before pregnancy was linked to autism or developmental delays. After detailed assessments of speech, ...
THE VACCINE MAKER MODERNA decided this past week to tell the world about bad news it had received from the federal government ...
Rejecting a recently developed Moderna flu vaccine, the HHS continues to distance itself from mRNA research and development.
Moderna will not commit to previous 2028 breakeven guidance as the ripple effects of the FDA’s refusal-to-file decision spread through its pipeline.
Mani Foroohar, M.D., of Leerink Partners, says that the decision reflects “how sharp the departure has been between the prior ...
HealthDay News — In a major blow to vaccine development, the US Food and Drug Administration (FDA) said it will not review Moderna’s application for the first mRNA-based flu shot. Dr Vinay Prasad, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results